-
-
The Compassher2 Trials (Comprehensive Use Of Pathologic Response Assessment To Optimize Therapy In Her2-Positive Breast Cancer): Compassher2 Residual Disease (Rd), A Double-Blinded, Phase III Randomized Trial Of T-Dm1 And Placebo Compared With T-Dm1
-
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
-
Cystic Fibrosis (CF) Foundation Registry
-
DCM Precision Medicine Study
-
Development and Implementation of Proteomics Analysis into the Inova Molecular Tumor Board
-
A Double-Blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR with Placebo in Female Subjects with Stress Urinary Incontinence
-
Early classification of advanced and unresectable melanoma response profiles via ctDNA monitoring and ctDNA based detection of relapse-associated neoantigens in resectable melanoma cases (Personalis CellFree)
-
Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation (EAA181)
-
Evaluate Cardiovascular Outcomes in Patients Treated with the Tricuspid Valve Repair System Pivotal (Triluminate)